BACKGROUND: Treatment of childhood acute lymphoblastic leukemia (ALL) may cause structural and functional brain damage. To find out the incidence of white matter changes during therapy, a prospective MRI study was designed, and the findings were correlated with neuropsychological evaluation. PROCEDURE: Thirty-three children with ALL underwent serial cranial MRI before, during, and after therapy. Twenty-eight of these children underwent also neuropsychological assessment at the end of treatment. They all received intravenous and intrathecal methotrexate for central nervous system (CNS) therapy, 15 patients received cranial irradiation in addition. RESULTS: Transient high-intensity white matter changes were observed by MRI in three children 9% (95% CI, 2-24%) who received chemotherapy only. The high-intensity changes were most prominent in the frontal lobes in two of these children. The children with white matter changes were significantly younger than those with normal MRI (2.8 vs. 7.4 years; mean). There was no correlation between neuropsychological tests and white matter changes, except in attention and in tests referring to the frontal areas in general. CONCLUSIONS: White matter changes are occasionally observed during therapy with the current Nordic protocols. Young children may be more susceptible to developing white matter changes after repeated intravenous methotrexate injections. There is no systematic correlation between neuropsychological deficits and MRI findings. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: Treatment of childhood acute lymphoblastic leukemia (ALL) may cause structural and functional brain damage. To find out the incidence of white matter changes during therapy, a prospective MRI study was designed, and the findings were correlated with neuropsychological evaluation. PROCEDURE: Thirty-three children with ALL underwent serial cranial MRI before, during, and after therapy. Twenty-eight of these children underwent also neuropsychological assessment at the end of treatment. They all received intravenous and intrathecal methotrexate for central nervous system (CNS) therapy, 15 patients received cranial irradiation in addition. RESULTS: Transient high-intensity white matter changes were observed by MRI in three children 9% (95% CI, 2-24%) who received chemotherapy only. The high-intensity changes were most prominent in the frontal lobes in two of these children. The children with white matter changes were significantly younger than those with normal MRI (2.8 vs. 7.4 years; mean). There was no correlation between neuropsychological tests and white matter changes, except in attention and in tests referring to the frontal areas in general. CONCLUSIONS: White matter changes are occasionally observed during therapy with the current Nordic protocols. Young children may be more susceptible to developing white matter changes after repeated intravenous methotrexate injections. There is no systematic correlation between neuropsychological deficits and MRI findings. Copyright 2000 Wiley-Liss, Inc.
Authors: Ida M Moore; Marilyn J Hockenberry; Cynthia Anhalt; Kathy McCarthy; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2011-09-21 Impact factor: 3.167
Authors: Marc H Bornstein; Sara Scrimin; Diane L Putnick; Fabia Capello; O Maurice Haynes; Simona de Falco; Modesto Carli; Marta Pillon Journal: J Pediatr Psychol Date: 2012-02-02
Authors: Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2014-01-25 Impact factor: 3.167